Yao, Chen
Sun, Hong-Wei
Lacey, Neal E. http://orcid.org/0000-0002-3633-5924
Ji, Yun
Moseman, E. Ashley
Shih, Han-Yu http://orcid.org/0000-0002-7525-5433
Heuston, Elisabeth F.
Kirby, Martha http://orcid.org/0000-0001-7157-7964
Anderson, Stacie
Cheng, Jun
Khan, Omar
Handon, Robin
Reilley, Julie
Fioravanti, Jessica http://orcid.org/0000-0001-6263-4306
Hu, Jinhui
Gossa, Selamawit
Wherry, E. John http://orcid.org/0000-0003-0477-1956
Gattinoni, Luca http://orcid.org/0000-0003-2239-3282
McGavern, Dorian B. http://orcid.org/0000-0001-9568-545X
O’Shea, John J. http://orcid.org/0000-0002-6456-9752
Schwartzberg, Pamela L. http://orcid.org/0000-0001-6318-9187
Wu, Tuoqi http://orcid.org/0000-0002-4003-1034
Article History
Received: 17 September 2018
Accepted: 16 April 2019
First Online: 17 June 2019
Competing interests
: E.J.W. has consulting agreements with and/or is on the scientific advisory board for Merck, Roche, Pieris, Elstar and Surface Oncology. E.J.W. has a patent licensing agreement on the PD-1 pathway with Roche/Genentech. Y.J. has stock in Cellular Biomedicine Group.